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ABSTRACT 27	
Objective: Regulation of energy balance depends on pro-opiomelanocortin (POMC)-28	
derived peptides and melanocortin-4 receptor (MC4R). Alpha-melanocyte stimulating 29	
hormone (α-MSH) is the predicted natural POMC-derived peptide that regulates 30	
energy balance. Desacetyl-α-MSH, the precursor for α-MSH, is present in brain and 31	
blood. Desacetyl-α-MSH is considered to be unimportant for regulating energy 32	
balance despite being more potent (compared with α-MSH) at activating the appetite-33	
regulating MC4R in vitro. Thus, the physiological role for desacetyl-α-MSH is still 34	
unclear. 35	
Methods: We created a novel mouse model to determine whether desacetyl-α-MSH 36	
plays a role in regulating energy balance. We engineered a knock in targeted QKQR 37	
mutation in the POMC protein cleavage site that blocks the production of both 38	
desacetyl-α-MSH and α-MSH from adrenocorticotropin (ACTH1-39).  39	
Results: The mutant ACTH1-39 (ACTHQKQR) functions similar to native ACTH1-39 40	
(ACTHKKRR) at the melanocortin 2 receptor (MC2R) in vivo and MC4R in vitro. Male 41	
and female homozygous mutant ACTH1-39 (Pomctm1/tm1) mice develop the 42	
characteristic melanocortin obesity phenotype. Replacement of either desacetyl-α-43	
MSH or α-MSH over 14 days into Pomctm1/tm1 mouse brain significantly reverses 44	
excess body weight and fat mass gained compared to wild type (WT) (Pomcwt/wt) 45	
mice. Here, we identify both desacetyl-α-MSH and α-MSH peptides as regulators of 46	
energy balance and highlight a previously unappreciated physiological role for 47	
desacetyl-α-MSH. 48	
Conclusions: Based on these data we propose that there is potential to exploit the 49	
naturally occurring POMC-derived peptides to treat obesity but this relies on first 50	
understanding the specific function(s) for desacetyl-α-MSH and α-MSH.  51	
	 3	
Keywords: POMC, Obesity, Desacetyl-α-MSH, α-MSH, obese mouse model 52	
1. INTRODUCTION 53	
The melanocortin system plays a significant role in the regulation of energy balance 54	
(see reviews	[1-3]). However, little is known about which specific endogenous pro-55	
opiomelanocortin (POMC)-derived peptides are responsible for regulation of appetite, 56	
metabolism, and body weight. The POMC protein is inherently complex and is 57	
differentially cleaved into multiple peptides in a coordinated and tissue-specific 58	
manner [4]. POMC is a prohormone and its processing involves proteolytic cleavages 59	
at specific pairs of basic amino acids performed by enzymes, prohormone converting 60	
enzyme 1 (PC1), prohormone converting enzyme 2 (PC2) and carboxypeptidase E 61	
(CPE) (reviewed in [5]). In brain and pituitary pars distalis and pituitary pars 62	
intermedia, POMC is cleaved by PC1 to produce multiple peptides including ACTH1-63	
39 and β-lipotrophin (β-LPH). PC2 is selectively expressed in brain and pituitary pars 64	
intermedia and it cuts ACTH1-39 further at tandem dibasic residues, KKRR, to produce 65	
ACTH1-17 and corticotropin-like intermediate lobe peptide (CLIP). CPE subsequently 66	
removes basic amino acids at the C-terminus of ACTH1-17 to produce ACTH1-13. Post-67	
translational processing of ACTH1-13 produces desacetyl-α-MSH, α-MSH 68	
(monoacetylated) and diacetyl-α MSH. PC2 also cuts β-LPH to generate γ-LPH and 69	
β-endorphin. 70	
One POMC-derivative, β-endorphin, stimulates food intake [6-8] while four POMC-71	
derived peptides, ACTH1-39, α-MSH, β-MSH and γ2-MSH reduce food intake [6, 9, 72	
10]. A sixth peptide, desacetyl-α-MSH, also reduces food intake, but in 73	
pharmacological studies requires a 25-times higher dose than α-MSH [9]. For this 74	
reason, desacetyl-α-MSH has been considered to be unimportant for the regulation of 75	
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energy balance [5, 11, 12]. However, there is a higher abundance of desacetyl-α-MSH 76	
compared with α-MSH in rat hypothalamus [13, 14]. In addition, desacetyl-α-MSH 77	
(compared with α-MSH) is more potent at activating the appetite-regulating MC4R in 78	
vitro [1]. Thus, the physiological role of desacetyl-α-MSH still remains unclear. 79	
The melanocortin peptides differentially activate five melanocortin receptor (MCR) 80	
subtypes, each having unique tissue distributions and functions. MC3R and MC4R are 81	
highly expressed in the central nervous system and play key roles in regulating energy 82	
balance [15-17]. Multiple POMC-derived peptides activate MC3R and MC4R in vitro 83	
[18-20]. However, it is unknown whether these peptides have distinct or redundant 84	
roles in vivo [2]. Since studies have indicated that only pharmacologic concentrations 85	
of desacetyl-α-MSH (compared to α-MSH) inhibit food intake [9, 21], α-MSH is 86	
predicted to be the endogenous melanocortin peptide hormone that regulates energy 87	
balance. In addition, β-MSH is not present in rodents [22]. Here, we determined the 88	
direct contribution of desacetyl-α-MSH and α-MSH in regulating energy balance.  89	
 90	
2. MATERIALS AND METHODS 91	
2.1. Generation and maintenance of Pomctm1 targeted mutation mouse model. 92	
The objective of this study is to develop a mouse model with a targeted Pomc 93	
mutation that prevents production of desacetyl-α-MSH and α-MSH and then use this 94	
model to determine whether desacetyl-α-MSH plays a role in energy balance. Ozgene 95	
Pty Ltd (Bentley DC, WA, Australia) generated the Pomctm1Kgm† knock in mouse 96	
strain, the first targeted mutation (tm1) in the mouse Pomc gene that prevents ACTH1-97	
																																																								
† The registered nomenclature for this mouse model. 
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39 cleavage into ACTH1-17 and CLIP. We first validated that mutant ACTHQKQR 98	
(found in Pomctm1/tm1 mice) functions similar to wild type (WT) ACTHKKRR (found in 99	
Pomcwt/wt mice) both in vitro and in vivo (see Supplementary Data). A targeting vector 100	
was created containing mouse Pomc exon 3 KKRR proteolytic cleavage site mutated 101	
to QKQR with PGK-Neo selection cassette inserted downstream of WT exon 3. Lox P 102	
sites were inserted flanking WT exon 3 and the PGK-Neo selection cassette. The 103	
targeting vector was constructed from three fragments, the 5’homology arm, the 104	
3’homology arm and the lox P arm, which were all generated by PCR. Cre-105	
recombinase deletes the PGK-Neo cassette and WT exon 3 allowing the mutant 106	
QKQR exon 3 to be expressed. Following electroporation of the targeting construct 107	
into C57BL/6J Bruce4 embryonic stem (ES) cells, cells were selected for neomycin 108	
resistance. Southern blotting and PCR were used to confirm targeted ES cells. 109	
Euploid, targeted ES cells were then microinjected into Balb/cJ blastocysts and re-110	
implanted into pseudo-pregnant dams. Resultant chimeras were bred to C57BL/6J 111	
breeders to establish transmission. Black progeny that were heterozygous for the 112	
gene-targeted allele were then bred to Cre recombinase “delete” mice on C57BL/6J 113	
background (Ozgene Pty Ltd) to allow excision of the WT exon 3 and Neo selection 114	
cassette. Cre was then removed by breeding to C57BL/6J WT mice. Resulting mice 115	
were transferred to the Vernon Jensen Animal Unit at the University of Auckland 116	
(UOA) where the colony is maintained with heterozygous breeding pairs. Mice were 117	
transferred from the University of Auckland to University of Texas South Western 118	
Medical Center (UTSW) where the colony is maintained with triplicate heterozygous 119	
mouse breeding. 120	
Routine genotyping is performed by a PCR based strategy utilizing primers that 121	
anneal to Pomc exon 3 (forward 5’TGCATCCGGGCTTGCAAACTCGA3’ and 122	
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reverse 5’GGGGCAAGGAGGTTGAGAAAT3’) yielding an 820bp fragment. HaeII 123	
restriction enzyme is used to cleave the 802 bp fragment to yield 514bp, 234bp and 54 124	
bp fragments. The QKQR mutation destroyed one of the HaeII sites and therefore 125	
HaeII cleaves the homozygous KI to yield 568bp and 234bp fragments.  126	
 127	
2.2. Ethics and animal husbandry. 128	
All experimental procedures involving mice at the Vernon Jensen Animal Facility, 129	
UOA, were approved by the Auckland University Animal Ethics Committee and 130	
conformed to The Animal Welfare Act 1999. Animals were housed up to 6 per cage 131	
on wood-chip bedding and maintained at room ambient 20°C with a 12-h dark-light 132	
cycle (lights on at 07:00 h in a pathogen-free barrier facility. The mice were fed 133	
regular chow (Teklad Global 18% protein rodent diet 2018 [Harlan Laboratories, Inc., 134	
Madison, WI, USA]). All experimental procedures for the metabolic cages were 135	
performed at UTSW and were approved by the IACUC committee at UTSW. The 136	
Pomctm1Kgm mouse breeding colony was established at UTSW to produce mice for 137	
testing in metabolic cages. At UTSW, mice were bred and housed in a barrier facility 138	
at room ambient 22-24°C on a 12 h light/12 h dark cycle and were provided standard 139	
chow (2016; Harlan Teklad) as well as water ad libitum. All experimental procedures 140	
involving mice at University of Cambridge were carried out in accordance with the 141	
guidelines of the United Kingdom Home Office. Animals were kept under controlled 142	
temperature (22°C) and 12 h light, 12 h dark schedule (lights on 7:00-19.00). 143	
 144	
2.3. Growth and development. 145	
Groups comprising Pomcwt/wt, Pomcwt/tm1 and Pomctm1/tm1 mice of each sex were 146	
weighed biweekly from weaning until 19-20 weeks of age. Significant differences 147	
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were determined using two-way repeated-measures ANOVA and Bonferroni post-hoc 148	
test. Examination of both sexes allowed for assessment of sexually dimorphic 149	
phenotypes. At 27-30 weeks, the mice were fasted overnight before being euthanized 150	
with isoflurane, blood collected by cardiac puncture and nose-anus and anus-tail tip 151	
measurements recorded. Significant differences were determined using one-way 152	
ANOVA and Tukey’s post-hoc test.  153	
 154	
2.4. Body Composition. 155	
Body composition was analyzed by magnetic resonance imaging (MRI) at the 156	
University of Auckland and nuclear magnetic resonance (NMR) at UTSW. MRI was 157	
used to assess body composition of Pomcwt/wt, Pomcwt/tm1 and Pomctm1/tm1 mice and to 158	
compare body composition of male Pomctm1/tm1 mice following melanocortin peptide 159	
treatment. NMR (minispec, Bruker) was used to compare body composition prior to 160	
metabolic cage experiments. MRI was performed using a 4.7T horizontal bore magnet 161	
interfaced with a UnityInova spectrometer (Agilent Technologies, Santa Clara, CA, 162	
USA). The anaesthetized animals were placed in a 72mm ID circularly-polarized 163	
radio-frequency coil for imaging (m2m Imaging, Cleveland, OH, USA). Localizer 164	
images were used to determine the appropriate position and number of slices to ensure 165	
that all of the animal's tissue was included in the body composition assessment. The 166	
scans to determine the body composition of the animals used the three-point Dixon 167	
technique [23] on a set of contiguous, 1mm thick slices with a field-of-view of 110 x 168	
55 mm and the imaging matrix set to 256 x128. The repetition time (TR) was 1000 ms 169	
and the echo times were specified so that one in-phase image (0º) and two out-of-170	
phase images (-180º, 180º) were acquired. All image processing to extract the fat and 171	
lean-tissue images from the MRI data and to determine the body composition was 172	
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performed with MATLAB (Mathworks Inc., Natick, MA, USA) using previously 173	
described techniques [23]. Significant differences were determined using one-way 174	
ANOVA and Tukey’s post-hoc test. 175	
 176	
2.5. Metabolic Cages. 177	
Metabolic measurements were obtained for male and female Pomcwt/wt and 178	
Pomctm1/tm1 mice aged ~ 4-6 weeks fed a regular chow diet or a regular chow diet and 179	
switched to a high-fat diet for the duration of the time they were housed in metabolic 180	
cages. Before each experiment body composition ad libitum fed mice was assessed 181	
using NMR spectrometer and the mice were acclimatized to individual caging for 3-4 182	
days. Mice were then transferred to metabolic chambers for an additional 4-day 183	
acclimatization period with food provided ad libitum. Following acclimatization, 184	
energy expenditure (O2 consumption) was measured by indirect calorimetry and 185	
simultaneous locomotor activity was assessed by infrared light-beam frame 186	
surrounding the cage using TSE Labmaster monitoring system (TSE Systems GmbH, 187	
Bad Homburg, Germany). Average oxygen consumption was calculated for both light 188	
and dark periods and expressed per total or lean body mass. For locomotor activity 189	
analysis, beam beaks in X- and Y- axis (ambulatory activity) was measured and 190	
summed over dark and light periods. Significant differences were determined using 191	
two-way repeated measures ANOVA and Bonferroni post-hoc analysis or unpaired 192	
two-tail Student’s t test. 193	
 194	
2.6. Central melanocortin peptide treatment. 195	
We administered melanocortin peptides to mice continuously using osmotic mini 196	
pumps but first we determined using MALDI-TOF MS that α-MSH and desacetyl-α-197	
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MSH dissolved in PBS and stored at 37°C were stable over 14 days. Aliquots of α-198	
MSH and desacetyl-α-MSH dissolved in PBS that were prepared for treatment studies 199	
were incubated in Lo-bind eppendorf tubes at 37°C. At 7, 10 and 14 days aliquots 200	
were snap frozen at -80°C. After thawing, the aliquots were centrifuged at 13,000g for 201	
2 min at 4 °C. Spots (1 µL) of each supernatant were then spiked on a MALDI-TOF 202	
plate and dried for ≥ 30 min in a vacuum dessicator. Matrix (αCyano-4-203	
hydroxycinnamic acid in 50% acetonitrile in sterile water with 0.1% TFA) was 204	
applied manually over peptides and allowed to thoroughly dry before the plate was 205	
read in a Voyager DE-Pro Mass Spectrometer (Applied Biosystems). After dissolving 206	
in PBS, melanocortin peptides were primed overnight at 37 °C in osmotic mini pumps 207	
before being administered intracerebroventricular (i.c.v.) continuously over 14 days 208	
by osmotic mini pump infusions. Group-housed mice (n= 3-6 mice per cage) 209	
underwent stereotaxic surgery under isoflurane anesthesia to implant a cannula into 210	
the lateral cerebral ventricle with the following coordinates: anterior posterior 0.1 211	
mm, medial lateral 0.9 mm with one spacer dorsal ventral. An Alzet® mini osmotic 212	
pump (Model 1002, Bio-Scientific Pty Ltd., NSW, Australia) filled either with saline 213	
vehicle (USP-IV-IM, Demo Pharmaceutical Industry, Greece) or melanocortin 214	
peptide (delivering 0.05 µg, 0.5 µg or 5 µg of peptide/ 25g mouse body weight/day) 215	
was implanted subcutaneously and was attached to the cannula using a catheter (Alzet 216	
Brain Infusion Kit 3, Bio-Scientific Pty Ltd.). Mice were allowed to recover from 217	
surgery for ~2-4 hour before being returned to their group-housed cages. Individual 218	
body weights and food and water intake for each cage were monitored daily over 14 219	
days. All mice were monitored daily for signs of ill health (not eating, starry-fur, not 220	
moving). Significant differences were determined using two-way repeated measures 221	
ANOVA and Dunnett’s post-hoc analysis. 222	
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 223	
2.7. Statistical analysis. 224	
GraphPad Prism 7 software (GraphPad Software Inc., San Diego, CA) was used to 225	
perform all statistical analyses. Comparisons between groups were made by two-way 226	
or one-way repeated or non-repeated measures ANOVA with Tukey or Bonferroni 227	
post-hoc analysis, or by 2-tailed Student ‘t’ test as indicated. Changes in body weight 228	
over time comparisons were made using repeated two-way ANOVA. P<0.05 was 229	
considered statistically significant. Data are presented as mean ± SEM. 230	
 231	
3. RESULTS 232	
3.1.  A Pomc gene targeted mutation (Pomctm1) results in biologically active 233	
QKQR mutant ACTH1-39 hormone. 234	
Deletion in the Pomc gene results in obesity in both mice [24-26] and humans [27]. 235	
However, the Pomc null mouse is not suitable for determining specific POMC-236	
derived peptide functions since it lacks all POMC-derived peptides and does not 237	
develop functional adrenal glands [24, 26, 28]. Thus, we developed a unique mouse 238	
model (Pomctm1Kgm) with a targeted QKQR mutation in the POMC protein cleavage 239	
site that is required to produce desacetyl-α-MSH and α-MSH from ACTH1-39 (Figure 240	
1A).  241	
We performed a series of biochemical and physiological studies to validate biological 242	
activity for QKQR mutant ACTH1-39 (ACTHQKQR, see amino acid alignment, Figure 243	
1B). ACTHQKQR stimulates corticosterone production similar to native ACTH1-39 244	
(ACTHKKRR) in dexamethasone-suppressed Pomcwt/wt male mice (Supplementary 245	
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Figure 1A). The ACTHQKQR, like native ACTHKKRR, is biologically active at the 246	
MC4R in vitro (Supplementary Figure 1B). Pomctm1/tm1 mice develop functional 247	
adrenal glands and produce corticosterone levels similar to Pomcwt/wt mice 248	
(Supplementary Figure 1C). These results confirm that ACTHQKQR is produced and 249	
functional in Pomctm1/tm1 mice. 250	
 251	
3.2.  ACTHQKQR protein is not cleaved to produce desacetyl-α-MSH and α-MSH. 252	
We chose pituitary to validate that the QKQR mutation blocks ACTH1-39 cleavage in 253	
vivo because POMC is abundantly expressed in pituitary pars distalis and pars 254	
intermedia while lesser amounts of POMC are expressed in the arcuate nucleus of the 255	
hypothalamus. The pituitary pars intermedia is a good surrogate for the arcuate 256	
nucleus since they both express PC2, the enzyme required for cleaving ACTH1-39 to 257	
ACTH1-17. The pars distalis and posterior lobe of the pituiatry are helpful controls 258	
since the pars distalis expresses POMC but no PC2 while the posterior lobe of the 259	
pituitary does not express either POMC or PC2. 260	
To validate that ACTHQKQR protein is not cleaved, we used Matrix Assisted Laser 261	
Desorption/Ionization (MALDI)-Time-of-Flight (TOF) Mass Spectrometry (MS) of 262	
pituitary sections and lysates (see Supplementary Methods). MALDI-TOF MS 263	
imaging of pituitary sections confirms that diacetyl-α-MSH is present in Pomcwt/wt but 264	
not in Pomctm1/tm1 pars intermedia, while phospholipid (marker for pars distalis) [29] 265	
and vasopressin (marker for posterior pituitary lobe) [29] are present in the pars 266	
distalis and posterior lobe respectively, of both Pomcwt/wt and Pomctm1/tm1 mice 267	
(Figure 1C). In addition, a signal predicted to be Arg-CLIP (1-22; cleaved from the C-268	
terminus of ACTH1-39) is only detectable in Pomcwt/wt whole pituitary lysate 269	
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(Supplementary Figure 2A), while vasopressin, J peptide and a signal predicted to be 270	
β-LPH appear in both Pomcwt/wt and Pomctm1/tm1 whole pituitary lysate 271	
(Supplementary Figure 2A, B). ACTH1-39 and β-LPH are the predominant POMC-272	
derived peptides produced in pars distalis and diacetyl-α-MSH, α-MSH and β-LPH 273	
are the predominant POMC-derived peptides produced in pars intermedia. β-274	
endorphin was not detected here but under conditions of stress, β-LPH in pars 275	
intermedia is cleaved by PC2 to produce β-endorphin [30]. Thus, in the Pomctm1/tm1 276	
mouse only the ACTHQKQR is not cleaved in vivo to produce ACTH1-13 and Arg-277	
CLIP, while all other melanocortin peptides are produced through in vivo cleavage.   278	
 279	
3.3.  N-terminal acetylation of ACTHQKQR protein in whole pituitary lysate. 280	
Surprisingly, MALDI-TOF MS showed a clear signal at m/z 4638 that appears only in 281	
Pomctm1/tm1 and not in Pomcwt/wt whole pituitary lysate (Supplementary Figure 2B). 282	
We identified this peptide as N-terminal acetylated ACTHQKQR using 283	
immunoprecipitation and LC-MS/MS. We determined that acetylation of ACTHQKQR 284	
does not change ACTHQKQR functional coupling at the mouse MC4R in vitro and it 285	
abolishes ACTHQKQR functional coupling of the mouse MC2R (Supplementary Figure 286	
3A, B). Therefore, acetyl-ACTHQKQR produced in pituitary, presumably in pars 287	
intermedia where desacetyl-α-MSH is normally acetylated, is not expected to affect 288	
the phenotype of Pomctm1/tm1 mice. 289	
 290	
3.4.  Male and female Pomctm1/tm1 mice develop characteristic melanocortin 291	
obesity. 292	
Despite expressing non-acetylated and acetylated ACTHQKQR, which both functionally 293	
couple to the mouse MC4R in vitro, male and female Pomctm1/tm1 mouse body weights 294	
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are significantly increased compared to Pomcwt/wt and Pomcwt/tm1 mice starting at 4-6 295	
weeks of age (Figure 1D, G), due to increased lean and fat mass. Female and male 296	
Pomctm1/tm1 body lengths are ~5% and ~3% longer respectively, compared to 297	
Pomcwt/wt or Pomcwt/tm1 mice (Figure 1E, H). Quantitative magnetic resonance 298	
imaging (MRI) analysis of whole-body tissue composition at 26-29 weeks shows 299	
significant increases in fat mass in Pomctm1/tm1 male and Pomctm1/tm1 female mice 300	
compared with Pomcwt/wt mice (Figure 1F, I). These results indicate that the absence 301	
of desacetyl-α-MSH and α-MSH is sufficient to induce the characteristic 302	
melanocortin obesity phenotype, attributed to increased fat and lean mass as well as 303	
increased body length. 304	
 305	
3.5.  Pomctm1/tm1 mouse hyperphagia is exacerbated when mice are fed high-fat 306	
diet.  307	
We next sought to determine what parameters of energy balance are altered and are 308	
causing obesity in early age. Mice (4 weeks of age) were individually housed in 309	
metabolic cages to investigate how the absence of desacetyl-α-MSH and α-MSH 310	
affects feeding behavior and energy expenditure, before differences in body weight 311	
might confound interpretation. While all Pomctm1/tm1 mice exhibit hyperphagia, we 312	
observed that male Pomctm1/tm1 mice fed a low-fat diet (LFD) have increased food 313	
intake during the light phase, while females are hyperphagic during the dark phase 314	
(Figure 2A, B). This suggests that male Pomctm1/tm1 mice have an altered feeding 315	
pattern, with abnormal food intake during the light-cycle. A deficiency in POMC or 316	
MC4R associates with hyperphagia that is exaggerated by dark-cycle food 317	
consumption (reviewed in [31, 32]) and is sensitive to dietary fat content [33, 34]. 318	
Here, we show high-fat diet (HFD) exacerbates hyperphagia in male and female 319	
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Pomctm1/tm1 mice throughout the day (Figure 2A, B), suggesting that the absence of 320	
desacetyl-α-MSH and α-MSH promotes food intake and potentially increases the 321	
palatability of HFD. 322	
 323	
3.6.  High-fat diet reduced energy expenditure for male and female Pomctm1/tm1 324	
mice. 325	
Manipulations of the melanocortin system were previously shown to impair energy 326	
expenditure, thus contributing to the obesity phenotype [34, 35]. Here, we observed 327	
that neither oxygen consumption nor locomotor activity was significantly altered in 328	
mice fed a LFD (Figure 2C - F). Interestingly, male and female Pomctm1/tm1 mice fed 329	
HFD exhibit significantly reduced oxygen consumption compared to Pomcwt/wt mice 330	
(Figure 2C, D), without changes in locomotor activity (Figure 2E, F). These data 331	
suggest that Pomctm1/tm1 mice have reduced energy expenditure when exposed to a 332	
HFD regimen. 333	
 334	
3.7.  Central administration of either desacetyl-α-MSH or α-MSH reverses 335	
Pomctm1/tm1 mouse obesity. 336	
To determine whether replacement of each peptide alone can reverse the characteristic 337	
melanocortin obesity, we continuously administered incremental doses (0.03 -3.00 338	
nmol / 25 g body weight / day) of α-MSH or desacetyl-α-MSH into adult Pomctm1/tm1 339	
mouse brains over 14 days. First, we determined that α-MSH and desacetyl-α-MSH 340	
are stable under these treatment conditions (Supplementary Figure S4). We show that 341	
either α-MSH or desacetyl-α-MSH can significantly reduce body weight in 342	
Pomctm1/tm1 mice compared with vehicle-treated age- and sex-matched control 343	
Pomctm1/tm1 mice. Treatment with 5 µg α-MSH or 5 µg desacetyl-α-MSH similarly 344	
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reduced male or female body weight (Figure 4E, F). However, α-MSH is more potent 345	
than desacetyl-α-MSH at reducing female body weight since body weight was 346	
significantly reduced following either 0.05 µg or 0.50 µg desacetyl-α-MSH but not by 347	
corresponding α-MSH doses (Figure 3A, B, F). In contrast with females, α-MSH is 348	
not more potent than desacetyl-α-MSH at decreasing male Pomctm1/tm1 mouse body 349	
weight and furthermore, there is a trend for desacetyl-α-MSH to be more potent than 350	
α-MSH (0.05 µg and 0.50 µg doses) at reducing male body weight (Figure 3C, D, F). 351	
The decreased body weight is predominantly due to fat mass loss: body weight and 352	
percent body fat measured using MRI in male Pomctm1/tm1 mice treated with either α-353	
MSH or desacetyl-α-MSH are significantly reduced compared with vehicle-treated 354	
age-matched male Pomctm1/tm1 mice (Figure 4). The mice exhibited no signs of ill 355	
health over the 14 days of treatment and therefore these hormones do not appear to 356	
have any non-specific toxic effects. 357	
 358	
4. DISCUSSION 359	
The long-held myth that desacetyl-α-MSH is biologically unimportant for body 360	
weight regulation can now be put to rest. Our novel Pomctm1/tm1 mouse identifies 361	
desacetyl-α-MSH and α-MSH as both necessary for regulating mouse energy balance. 362	
We show that preventing the production of ACTH1-13 from ACTH1-39 results in a 363	
characteristic melanocortin obesity phenotype. Furthermore, pharmacological 364	
administration of desacetyl-α-MSH or α-MSH is sufficient to reverse this phenotype. 365	
Previously, central α-MSH administration has been shown to decrease rodent food 366	
intake and body weight [10, 36, 37], but we are the first to show potent effects for 367	
desacetyl-α-MSH decreasing mouse body weight. We show this because in our study, 368	
desacetyl-α-MSH is administered to a mouse that does not make any endogenous 369	
	 16	
desacetyl-α-MSH or α-MSH. This leads to the question as to why central 370	
administration of desacetyl-α-MSH in Pomcwt/wt rodents does not decrease food intake 371	
similar to α-MSH [9]. We hypothesize that endogenous desacetyl-α-MSH and α-MSH 372	
prevent exogenously administered desacetyl-α-MSH from reducing food intake and 373	
body weight in Pomcwt/wt rodents. We propose that the balance between endogenous 374	
desacetyl-α-MSH and α-MSH levels dictates the regulation of mammalian energy 375	
homeostasis and furthermore we propose the balance of these peptides could be 376	
sexually dimorphic. Here we show sensitivity to desacetyl-α-MSH and α-MSH 377	
induced weight loss differs between the sexes; male mice exhibit similar sensitivity to 378	
desacetyl-α-MSH and α-MSH while female mice are more sensitive to α-MSH 379	
compared with desacetyl-α-MSH. This adds to a list of sexually dimorphic differences 380	
reported for POMC-derived peptide regulation of energy homeostasis [38-42]. 381	
Leptin has been shown to stimulate N-terminal acetylation of desacetyl-α-MSH to 382	
generate α-MSH in the rodent hypothalamus [12]. α-MSH is believed to be the 383	
biologically active melanocortin hormone mediating leptin inhibition of food intake 384	
because desacetyl-α-MSH, compared with α-MSH, was shown to rapidly degrade in 385	
the hypothalamus [12]. However, our study shows that desacetyl-α-MSH and α-MSH 386	
are similarly effective at reducing Pomctm1/tm1 mouse body weight when continuously 387	
infused at physiological levels into the lateral ventricle. Guo et. al. measured ~0.15 388	
pmol α-MSH and ~0.58 pmol desacetyl-α-MSH in C57BL/6J mouse hypothalamus 389	
[12]. The lowest effective dose of either hormone that we infused i.c.v. into a 35g 390	
mouse is 0.029 pmol/minute and therefore if desacetyl-α-MSH is rapidly degraded in 391	
vivo it must trigger a rapid response prior to degradation. Importantly, we determined 392	
that both α-MSH and desacetyl-α-MSH are stable when stored in PBS at 37 °C for 14 393	
	 17	
days, which are the in vivo conditions for the osmotic mini pumps. Therefore, in our 394	
study the osmotic mini pumps should always be pumping intact hormones. 395	
Our data also suggest for the first time that ACTH1-39 is not sufficient to regulate 396	
mouse body weight despite ACTH1-39 having full agonist activity at the MC4R 397	
(Supplementary Figure 3A) and the ability of exogenous ACTH1-24 administered to 398	
rodent brain to cause decreased food intake [43]. However, it is unclear whether 399	
endogenous ACTH1-39 is produced in the brain and if it is, it may not be expressed 400	
when and where MC4R are expressed. The major end-products of POMC processing 401	
detected in brain hypothalamus are desacetyl-α-MSH and β-endorphin [44, 45] while 402	
α-MSH and acetylated β-endorphin expression predominate in the brain stem [44]. 403	
Hence, Pomctm1/tm1 mouse brain is expected to express acetyl-ACTHQKQR in brain 404	
stem and yet this is not sufficient to regulate Pomctm1/tm1 mouse body weight. The 405	
acetylation reaction required for producing α-MSH is documented to occur at 406	
desacetyl-α-MSH N-terminus [4, 44, 45]. However, here we show that N-terminal 407	
acetylation occurs on ACTH1-39 when cleavage of ACTH1-39 to ACTH1-17 is 408	
prevented. Therefore in the Pomctm1/tm1 mouse, all cells and tissues that should 409	
normally express α-MSH are expected to express acetyl-ACTHQKQR.  410	
A disadvantage for our novel model is that the QKQR ACTH mutation is knocked in 411	
the mouse genome during embryogenesis and therefore it is possible that the absence 412	
of desacetyl-α-MSH and α-MSH during development contributes to the obese 413	
Pomctm1/tm1 mouse phenotype. Furthermore, our model has global removal of 414	
desacetyl-α-MSH and α-MSH and therefore we do not know whether the obese 415	
Pomctm1/tm1 mouse phenotype is due to the removal of these peptides in the brain, in 416	
the periphery, or in both brain and periphery. POMC is most abundantly expressed in 417	
the pituitary gland and expressed in lower abundance in the arcuate nucleus of the 418	
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hypothalamus, the brainstem, and in several peripheral tissues including skin, 419	
pancreas, intestine, heart and reproductive organs	[1]. However, our results do 420	
indicate that pituitary and adrenal gland development and function are unaltered in 421	
our model, as supported by normal histology and corticosterone levels respectively. 422	
This does not reflect the EC50 for ACTHQKQR that is 82-fold less than the EC50 for 423	
ACTHKKRR coupling to mMC2R (Supplementary Figure S3). We hypothesize that the 424	
negative feedback regulation of pituitary pars distalis ACTHQKQR production is 425	
significantly reduced resulting in a build-up of circulating ACTHQKQR.  ACTHQKQR is 426	
a full agonist (Supplementary Figure S3) at the mMC2R and this build- 427	
up of ACTHQKQR would account for the normal corticosterone levels in the Pomctm1/tm1 428	
mouse. The development of a conditional Pomctm1/tm1 mouse model should resolve 429	
these issues. 430	
For over 15 years we have understood that POMC-derived peptide hormones are 431	
required for regulation of food intake and energy expenditure but only now do we 432	
show that desacetyl-α-MSH and α-MSH are both key endogenous POMC-derived 433	
peptides responsible for mouse regulation of appetite, metabolism, and body weight. 434	
We hypothesize that physiological and environmental factors differentially regulate 435	
endogenous POMC-derived peptide processing leading to dynamic changes in 436	
abundance of each peptide produced in specific cell types in brain and pituitary, and 437	
these dynamic changes culminate in the regulation of appetite, metabolism and body 438	
weight. The recently discovered cannabinoid-induced ‘munchies’ mediated through 439	
POMC neurons in the brain, turning up the production of β-endorphin while turning 440	
down the production of α-MSH [46] supports this hypothesis. Our data could suggest 441	
that there is potential to exploit the naturally occurring POMC-derived peptides to 442	
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treat obesity and type-2 diabetes but this relies on first understanding the specific 443	
function(s) for desacetyl-α-MSH and α-MSH in the brain and the periphery.  444	
 445	
5. CONCLUSION 446	
We show here that desacetyl-α-MSH is indeed biologically active in vivo and like α-447	
MSH it can reduce mouse body weight and fat mass. Therefore, our study highlights a 448	
need to understand how endogenous desacetyl-α-MSH and α-MSH levels correlate 449	
with measures of energy balance and whether there are distinct or redundant roles for 450	
these POMC-derived peptides in vivo.  451	
 452	
AUTHORS CONTRIBUTIONS 453	
K.G.M. was responsible for the overall experimental design in Auckland, New 454	
Zealand. A.C., S.L. and J.K.E. were responsible for the experimental design and data 455	
analysis for the metabolic cage experiments at The University of Texas Southwestern 456	
Medical Center, USA. S.B., K.H., K. V B., A.S., and B.S. maintained the mouse 457	
colony at the University of Auckland, weighed mice, performed i.c.v. surgeries, 458	
euthanized mice, harvested tissues, analyzed data and contributed to writing of the 459	
manuscript. A.M. trained and supervised researchers performing i.c.v. surgeries. K.H. 460	
C.B. and M.M performed mass spectrometry on tissue and lysates and A.G. 461	
performed imaging mass spectrometry on pituitary. P.W.R.H., R.K. and M.A.B. 462	
synthesized native and mutant ACTH peptides. R.B. performed cell culture and 463	
adenylyl cyclase assays and analyzed this data. B.P. performed MRI and developed 464	
MRI data analysis. A.C., K.T., S.P. and K.H. performed testing of ACTH peptides in 465	
vitro and in vivo. K.G.M. with help from A.C., S.L and J.K.E. wrote the manuscript 466	
that was reviewed by all authors. 467	
	 20	
 468	
ACKNOWLEDGEMENTS 469	
We thank J. Ross for help with MRI imaging analysis, K. Van Bysterveldt and 470	
M.Oudshoorn for help with mouse colony maintenance, harvesting tissues and 471	
preparing tissues for histology, K. Van Bysterveldt for help with cell culture and 472	
adenylyl cyclase assays, S. Amirapu and S. Cormack for help with histology and E. 473	
Thorstensen for steroid hormone assays. We received funding from the following 474	
New Zealand and University of Auckland funding bodies: The Marsden Fund, 475	
Auckland Medical Research Foundation, Maurice and Phyllis Paykel Trust, Maurice 476	
Wilkins Centre for Biodiscovery and Faculty Research and Development Fund. We 477	
also thank the Program Project Grant Core and Mouse Metabolic Phenotyping Core at 478	
The University of Texas Southwestern Medical Center at Dallas (supported by NIH 479	
grants PL1 DK081182 and UL1RR024923). This work was supported by NIH grant 480	
R37DK053301 to J.K.E. A.C is a Canadian Diabetes Association Post-doctoral 481	
Fellow. The work at Cambridge UK, was supported by Medical Research Council 482	
(MRC) (Award G108/617). A.P.C. was funded by the MRC Metabolic Disease Unit 483	
(MRC_MC_UU_12012/1). K.M.T. was supported by the Agency for Science 484	
Technology and Research (A*STAR) Singapore. 485	
 486	
CONFLICTS OF INTEREST 487	
The authors declare that no conflicts of interest exist.  488	
 489	
APPENDIX.  SUPPLEMENTARY DATA 490	
Supplementary data includes methods and three supplementary figures. 491	
 492	
	 21	
REFERENCES 493	 [1]	 Mountjoy,	K.G.,		2010.	Functions	for	pro-opiomelanocortin-	derived	494	 peptides	in	obesity	and	diabetes.	Biochem.	J.	428:	305-324.	495	 [2]	 Coll,	A.P.,		2007.	Effects	of	pro-opiomelanocortin	(POMC)	on	food	intake	496	 and	body	weight:	mechanisms	and	therapeutic	potential?	Clin.	Sci.	113:	171-182.	497	 [3]	 Cone,	R.D.,		2006.	Studies	on	the	physiological	functions	of	the	498	 melanocortin	system.	Endocr.	Rev.	27:	736-749.	499	 [4]	 Pritchard,	L.E.,	White,	A.,		2007.	Neuropeptide	processing	and	its	impact	500	 on	melanocortin	pathways.	Endocrinology	148:	4201-4207.	501	 [5]	 Pritchard,	L.E.,	Turnbull,	A.V.,	White,	A.,		2002.	Pro-opiomelanocortin	502	 processing	in	the	hypothalamus:	impact	on	melanocortin	signalling	and	obesity.	503	 J.	Endocrinol.	172:	411-421.	504	 [6]	 Tsujii,	S.,	Bray,	G.A.,		1989.	Acetylation	alters	the	feeding	response	to	MSH	505	 and	beta-endorphin.	Brain	Res.	Bull.	23:	165-169.	506	 [7]	 Appleyard,	S.M.,	Hayward,	M.,	Young,	J.I.,	Butler,	A.A.,	Cone,	R.D.,	507	 Rubinstein,	M.,	et	al.,		2003.	A	role	for	the	endogenous	opioid	beta-endorphin	in	508	 energy	homeostasis.	Endocrinology	144:	1753-1760.	509	 [8]	 Low,	M.J.,	Hayward,	M.D.,	Appleyard,	S.M.,	Rubinstein,	M.,		2003.	State-510	 dependent	modulation	of	feeding	behavior	by	proopiomelanocortin-derived	511	 beta-endorphin.	Ann.	N.	Y.	Acad.	Sci.	994:	192-201.	512	 [9]	 Abbott,	C.R.,	Rossi,	M.,	Kim,	M.,	AlAhmed,	S.H.,	Taylor,	G.M.,	Ghatei,	M.A.,	et	513	 al.,		2000.	Investigation	of	the	melanocyte	stimulating	hormones	on	food	intake.	514	 Lack	Of	evidence	to	support	a	role	for	the	melanocortin-3-receptor.	Brain	Res.	515	 869:	203-210.	516	
	 22	
[10]	 Millington,	G.W.,	Tung,	Y.C.,	Hewson,	A.K.,	O'Rahilly,	S.,	Dickson,	S.L.,		2001.	517	 Differential	effects	of	alpha-,	beta-	and	gamma(2)-melanocyte-stimulating	518	 hormones	on	hypothalamic	neuronal	activation	and	feeding	in	the	fasted	rat.	519	 Neuroscience	108:	437-445.	520	 [11]	 Harrold,	J.A.,	Williams,	G.,		2006.	Melanocortin-4	receptors,	beta-MSH	and	521	 leptin:	key	elements	in	the	satiety	pathway.	Peptides	27:	365-371.	522	 [12]	 Guo,	L.,	Munzberg,	H.,	Stuart,	R.C.,	Nillni,	E.A.,	Bjorbaek,	C.,		2004.	N-523	 acetylation	of	hypothalamic	alpha-melanocyte-stimulating	hormone	and	524	 regulation	by	leptin.	Proc.	Natl.	Acad.	Sci.	U.	S.	A.	101:	11797-11802.	525	 [13]	 Emeson,	R.B.,	Eipper,	B.A.,		1986.	Characterization	of	pro-526	 ACTH/endorphin-derived	peptides	in	rat	hypothalamus.	J.	Neurosci.	6:	837-849.	527	 [14]	 Frese,	C.K.,	Boender,	A.J.,	Mohammed,	S.,	Heck,	A.J.,	Adan,	R.A.,	Altelaar,	528	 A.F.,		2013.	Profiling	of	diet-induced	neuropeptide	changes	in	rat	brain	by	529	 quantitative	mass	spectrometry.	Anal.	Chem.	85:	4594-4604.	530	 [15]	 Huszar,	D.,	Lynch,	C.A.,	Fairchild-Huntress,	V.,	Dunmore,	J.H.,	Fang,	Q.,	531	 Berkemeier,	L.R.,	et	al.,		1997.	Targeted	disruption	of	the	melanocortin-4	532	 receptor	results	in	obesity	in	mice.	Cell	88:	131-141.	533	 [16]	 Chen,	A.S.,	Marsh,	D.J.,	Trumbauer,	M.E.,	Frazier,	E.G.,	Guan,	X.M.,	Yu,	H.,	et	534	 al.,		2000.	Inactivation	of	the	mouse	melanocortin-3	receptor	results	in	increased	535	 fat	mass	and	reduced	lean	body	mass.	Nat.	Genet.	26:	97-102.	536	 [17]	 Butler,	A.A.,	Kesterson,	R.A.,	Khong,	K.,	Cullen,	M.J.,	Pelleymounter,	M.A.,	537	 Dekoning,	J.,	et	al.,		2000.	A	unique	metabolic	syndrome	causes	obesity	in	the	538	 melanocortin-3	receptor-deficient	mouse.	Endocrinology	141:	3518-3521.	539	 [18]	 Roselli-Rehfuss,	L.,	Mountjoy,	K.G.,	Robbins,	L.S.,	Mortrud,	M.T.,	Low,	M.J.,	540	 Tatro,	J.B.,	et	al.,		1993.	Identification	of	a	receptor	for	gamma	melanotropin	and	541	
	 23	
other	proopiomelanocortin	peptides	in	the	hypothalamus	and	limbic	system.	542	 Proc.	Natl.	Acad.	Sci.	U.	S.	A.	90:	8856-8860.	543	 [19]	 Mountjoy,	K.G.,	Mortrud,	M.T.,	Low,	M.J.,	Simerly,	R.B.,	Cone,	R.D.,		1994.	544	 Localization	of	the	melanocortin-4	receptor	(MC4-R)	in	neuroendocrine	and	545	 autonomic	control	circuits	in	the	brain.	Mol.	Endocrinol.	8:	1298-1308.	546	 [20]	 Mountjoy,	K.G.,	Kong,	P.L.,	Taylor,	J.A.,	Willard,	D.H.,	Wilkison,	W.O.,		2001.	547	 Melanocortin	receptor-mediated	mobilization	of	intracellular	free	calcium	in	548	 HEK293	cells.	Physiol.	Genomics	5:	11-19.	549	 [21]	 Mountjoy,	K.G.,	Wu,	C.S.,	Cornish,	J.,	Callon,	K.E.,		2003.	alpha-MSH	and	550	 desacetyl-alpha-MSH	signaling	through	melanocortin	receptors.	Ann.	N.	Y.	Acad.	551	 Sci.	994:	58-65.	552	 [22]	 Lee,	Y.S.,	Challis,	B.G.,	Thompson,	D.A.,	Yeo,	G.S.,	Keogh,	J.M.,	Madonna,	553	 M.E.,	et	al.,		2006.	A	POMC	variant	implicates	beta-melanocyte-stimulating	554	 hormone	in	the	control	of	human	energy	balance.	Cell	Metab.	3:	135-140.	555	 [23]	 Glover,	G.H.,		1991.	Multipoint	Dixon	technique	for	water	and	fat	proton	556	 and	susceptibility	imaging.	J.	Magn.	Reson.	Imaging	1:	521-530.	557	 [24]	 Yaswen,	L.,	Diehl,	N.,	Brennan,	M.B.,	Hochgeschwender,	U.,		1999.	Obesity	558	 in	the	mouse	model	of	pro-opiomelanocortin	deficiency	responds	to	peripheral	559	 melanocortin	[see	comments].	Nat.	Med.	5:	1066-1070.	560	 [25]	 Smart,	J.L.,	Low,	M.J.,		2003.	Lack	of	proopiomelanocortin	peptides	results	561	 in	obesity	and	defective	adrenal	function	but	normal	melanocyte	pigmentation	in	562	 the	murine	C57BL/6	genetic	background.	Ann.	N.	Y.	Acad.	Sci.	994:	202-210.	563	 [26]	 Tung,	Y.C.,	Piper,	S.J.,	Yeung,	D.,	O'Rahilly,	S.,	Coll,	A.P.,		2006.	A	564	 comparative	study	of	the	central	effects	of	specific	proopiomelancortin	(POMC)-565	
	 24	
derived	melanocortin	peptides	on	food	intake	and	body	weight	in	pomc	null	566	 mice.	Endocrinology	147:	5940-5947.	567	 [27]	 Krude,	H.,	Biebermann,	H.,	Luck,	W.,	Horn,	R.,	Brabant,	G.,	Gruters,	A.,		568	 1998.	Severe	early-onset	obesity,	adrenal	insufficiency	and	red	hair	569	 pigmentation	caused	by	POMC	mutations	in	humans.	Nat.	Genet.	19:	155-157.	570	 [28]	 Coll,	A.P.,	Challis,	B.G.,	Yeo,	G.S.,	Snell,	K.,	Piper,	S.J.,	Halsall,	D.,	et	al.,		2004.	571	 The	effects	of	proopiomelanocortin	deficiency	on	murine	adrenal	development	572	 and	responsiveness	to	adrenocorticotropin.	Endocrinology	145:	4721-4727.	573	 [29]	 Larkin,	S.,	Ansorge,	O.,	Development	and	Microscopic	Anatomy	of	the	574	 Pituitary	Gland,	in:	L.J.	De	Groot,	G.	Chrousos,	K.	Dungan,	K.R.	Feingold,	A.	575	 Grossman,	J.M.	Hershman,	C.	Koch,	M.	Korbonits,	R.	McLachlan,	M.	New,	J.	Purnell,	576	 R.	Rebar,	F.	Singer,	A.	Vinik	(Eds.),	Endotext,	South	Dartmouth	(MA),	2000.	577	 [30]	 Madden,	J.t.,	Akil,	H.,	Patrick,	R.L.,	Barchas,	J.D.,		1977.	Stress-induced	578	 parallel	changes	in	central	opioid	levels	and	pain	responsiveness	in	the	rat.	579	 Nature	265:	358-360.	580	 [31]	 Garfield,	A.S.,	Li,	C.,	Madara,	J.C.,	Shah,	B.P.,	Webber,	E.,	Steger,	J.S.,	et	al.,		581	 2015.	A	neural	basis	for	melanocortin-4	receptor-regulated	appetite.	Nat.	582	 Neurosci.	18:	863-871.	583	 [32]	 Krashes,	M.J.,	Lowell,	B.B.,	Garfield,	A.S.,		2016.	Melanocortin-4	receptor-584	 regulated	energy	homeostasis.	Nat.	Neurosci.	19:	206-219.	585	 [33]	 Butler,	A.A.,		2006.	The	melanocortin	system	and	energy	balance.	Peptides	586	 27:	281-290.	587	 [34]	 Butler,	A.A.,	Marks,	D.L.,	Fan,	W.,	Kuhn,	C.M.,	Bartolome,	M.,	Cone,	R.D.,		588	 2001.	Melanocortin-4	receptor	is	required	for	acute	homeostatic	responses	to	589	 increased	dietary	fat.	Nat.	Neurosci.	4:	605-611.	590	
	 25	
[35]	 Berglund,	E.D.,	Liu,	T.,	Kong,	X.,	Sohn,	J.W.,	Vong,	L.,	Deng,	Z.,	et	al.,		2014.	591	 Melanocortin	4	receptors	in	autonomic	neurons	regulate	thermogenesis	and	592	 glycemia.	Nat.	Neurosci.	17:	911-913.	593	 [36]	 McMinn,	J.E.,	Wilkinson,	C.W.,	Havel,	P.J.,	Woods,	S.C.,	Schwartz,	M.W.,		594	 2000.	Effect	of	intracerebroventricular	alpha-MSH	on	food	intake,	adiposity,	c-595	 Fos	induction,	and	neuropeptide	expression.	American	Journal	of	Physiology	-	596	 Regulatory	Integrative	&	Comparative	Physiology	279:	R695-703.	597	 [37]	 Eerola,	K.,	Nordlund,	W.,	Virtanen,	S.,	Dickens,	A.M.,	Mattila,	M.,	Ruohonen,	598	 S.T.,	et	al.,		2013.	Lentivirus-mediated	alpha-melanocyte-stimulating	hormone	599	 overexpression	in	the	hypothalamus	decreases	diet	induced	obesity	in	mice.	J.	600	 Neuroendocrinol.	25:	1298-1307.	601	 [38]	 Burke,	L.K.,	Doslikova,	B.,	D'Agostino,	G.,	Greenwald-Yarnell,	M.,	602	 Georgescu,	T.,	Chianese,	R.,	et	al.,		2016.	Sex	difference	in	physical	activity,	energy	603	 expenditure	and	obesity	driven	by	a	subpopulation	of	hypothalamic	POMC	604	 neurons.	Mol	Metab	5:	245-252.	605	 [39]	 Bumaschny,	V.F.,	Yamashita,	M.,	Casas-Cordero,	R.,	Otero-Corchon,	V.,	de	606	 Souza,	F.S.,	Rubinstein,	M.,	et	al.,		2012.	Obesity-programmed	mice	are	rescued	by	607	 early	genetic	intervention.	J.	Clin.	Invest.	122:	4203-4212.	608	 [40]	 Nohara,	K.,	Zhang,	Y.,	Waraich,	R.S.,	Laque,	A.,	Tiano,	J.P.,	Tong,	J.,	et	al.,		609	 2011.	Early-life	exposure	to	testosterone	programs	the	hypothalamic	610	 melanocortin	system.	Endocrinology	152:	1661-1669.	611	 [41]	 Gelez,	H.,	Poirier,	S.,	Facchinetti,	P.,	Allers,	K.A.,	Wayman,	C.,	Bernabe,	J.,	et	612	 al.,		2010.	Neuroanatomical	distribution	of	the	melanocortin-4	receptors	in	male	613	 and	female	rodent	brain.	J.	Chem.	Neuroanat.	40:	310-324.	614	
	 26	
[42]	 Lippert,	R.N.,	Ellacott,	K.L.,	Cone,	R.D.,		2014.	Gender-specific	roles	for	the	615	 melanocortin-3	receptor	in	the	regulation	of	the	mesolimbic	dopamine	system	in	616	 mice.	Endocrinology	155:	1718-1727.	617	 [43]	 Poggioli,	R.,	Vergoni,	A.V.,	Bertolini,	A.,		1986.	ACTH-(1-24)	and	alpha-MSH	618	 antagonize	feeding	behavior	stimulated	by	kappa	opiate	agonists.	Peptides	7:	619	 843-848.	620	 [44]	 Eberle,	A.N.,	1988i	The	Melanotropins.	Chemistry,	Physiology	and	621	 Mechanisms	of	action.,	S.	Karger	Publishers,	Basel.	622	 [45]	 Eberle,	A.N.,	Proopiomelanocortin	and	the	Melanocortin	Peptides,	in:	R.D.	623	 Cone	(Ed.),	The	Melanocortin	Receptors,	Humana	Press	Inc,	Totowa,	NJ,	2000,	pp.	624	 3-67.	625	 [46]	 Koch,	M.,	Varela,	L.,	Kim,	J.G.,	Kim,	J.D.,	Hernandez-Nuno,	F.,	Simonds,	S.E.,	626	 et	al.,		2015.	Hypothalamic	POMC	neurons	promote	cannabinoid-induced	627	 feeding.	Nature	519:	45-50.	628	
 629	
 630	
FIGURE LEGENDS 631	
 632	
Figure 1: Generation of Pomctm1/tm1 mice that develop the characteristic 633	
melanocortin obese phenotype. 634	
A, Schematic of targeted Pomc allele for knock-in of QKQR mutation into Pomc 635	
exon 3 with resulting impact on pre-POMC processing and ACTH1-13 production. 636	
B, Amino acid sequence alignments for native and mutant ACTH1-39 molecule.  637	
C, MALDI imaging MS shows ACTH1-13 is successfully deleted from Pomctm1/tm1 638	
mouse pituitary. Mass-to-charge (m/z) signals that delineate the pars distalis (PD, m/z 639	
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835 in blue represents phospholipid) and posterior lobe (P, m/z 1086 in red represents 640	
vasopressin) are shown. In addition, diacetyl-α-MSH (m/z 1706 in green) is detected 641	
in the pars intermedia (PI) of Pomcwt/wt but not Pomctm1/tm1 tissue. Scale bars = 500 642	
µM. 643	
D and G, Body weights of mice fed a regular-chow diet from weaning. Significant 644	
difference determined using two-way repeated-measures ANOVA and Bonferroni 645	
post-hoc test between Pomcwt/wt and Pomctm1/tm1. *, p< 0.05; **, p<0.01; ***, p < 646	
0.001 or using paired Student ‘t’ test between Pomcwt/wt and Pomctm1/tm1; male #, 647	
p<0.05; female ##, p<0.01 648	
E and H, Body length measured at 27-30 weeks for mice fed a regular-chow diet 649	
from weaning. Data are shown as mean ± SEM. Significant differences determined 650	
using one-way ANOVA and Tukey’s post-hoc test. *, p< 0.05; **, p<0.01 651	
F and I, Percent body fat calculated from 6 MRI Dixon images/mouse. Data are 652	
shown as mean ± SEM for mice aged 26-29 weeks and fed a regular-chow diet. 653	
Significant differences determined using one-way ANOVA and Tukey’s post-hoc 654	
test. ***, p<0.001; ****, p<0.0001 655	
 656	
Figure 2: Food intake and energy expenditure for male and female Pomcwt/wt and 657	
Pomctm1/tm1 mice. 658	
A and B, Food intake was automatically measured in metabolic cages for mice at 4 659	
weeks of age and fed regular chow for 4 days and then switched to high-fat diet for 4 660	
days (n = 5-6 mice/group). Mice were acclimatized to the metabolic cages for 5 days 661	
prior to experiments. Data are shown as average food intake ± SEM per light cycle 662	
over 4 consecutive days for males and females. Significant differences determined 663	
	 28	
using either two-way repeated measures ANOVA and Bonferroni post-hoc analysis or 664	
unpaired two-tail Student’s t test. *, p<0.05; ***, p<0.001 665	
C and D, Oxygen consumption (VO2) measured in metabolic cages for the same mice 666	
shown in A and B. Data shown as average VO2 per light cycle ± SEM over 4 667	
consecutive days for males and females. Significant differences determined using 668	
either two-way repeated measures ANOVA and Bonferroni post-hoc analysis or 669	
unpaired two-tail Student’s t test. *, p<0.05; **, p<0.01 670	
E and F, Locomotor activity measured in metabolic cages for same mice as shown in 671	
A and B. Data are shown as total activity per light cycle ± SEM over 4 consecutive 672	
days for males and females. No significant differences were determined using either 673	
two-way repeated measures ANOVA and Bonferroni post-hoc analysis or unpaired 674	
two-tail Student’s t test. 675	
 676	
Figure 3: Central α-MSH or desacetyl-α-MSH treatments reduce male and 677	
female Pomctm1/tm1 mouse body weight. 678	
A, B, C, D, E, F Administration (i.c.v.) of α-MSH or desacetyl-α-MSH compared to 679	
vehicle treatment reduced Pomctm1/tm1 mouse body weight. At the start of treatment 680	
male mice were aged 23-31 weeks and female mice were aged 29-31 weeks. Vehicle 681	
or peptide dose (µg/25g mouse body weight on day1/day) was continuously 682	
administered over 14 days. Combined data are shown as mean ± SEM for two 683	
independent experiments. A- D; Significant differences determined using two-way 684	
repeated measures ANOVA and Dunnett’s post-hoc analysis. E, F: Significant 685	
differences determined using two-way ANOVA and Dunnett’s post-hoc analysis.  686	
*, p<0.05; **, p<0.01; ***, p<0.001. 687	
 688	
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Figure 4: Central α-MSH or desacetyl-α-MSH treatment reduces male 689	
Pomctm1/tm1 mouse fat mass. 690	
A and C, Mean body weight ± SEM for male Pomctm1/tm1 mice (n = 3 group) after 14 691	
days i.c.v administration of vehicle, α-MSH or desacetyl-α-MSH. 692	
B and D, Percent body fat ± SEM determined by MRI for male Pomctm1/tm1 mice 693	
shown in A and C after 14 days i.c.v administration of vehicle, α-MSH or desacetyl-694	
α-MSH. Significant differences between vehicle and peptide treatment determined 695	
using unpaired, two-tailed Student’s t test. *, p<0.05; **, p<0.01; ***, p<0.001 696	
E, Representative MRI images for mice presented in A, - D. Fat and lean tissues 697	
represented as green and red, respectively. 698	
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SUPPLEMENTARY	DATA	700	
	701	 	702	
MATERIALS	and	METHODS	703	
	704	
	705	
1.  Materials.  706	
Diacetyl-α-MSH, α-MSH, desacetyl-α-MSH, β-MSH and ACTH1-24 were purchased 707	
from Bachem AG (Bubendorf, Switzerland). Native ACTH1-39, QKQR mutant 708	
ACTH1-39, KGGR mutant ACTH1-39, KQRQ mutant ACTH1-39 and acetyl-QKQR 709	
mutant ACTH1-39 were purchased from Pepscan (Zuiderstuisweg 2, The Netherlands) 710	
or synthesized in-house. A rabbit polyclonal antibody (KM4) that specifically 711	
recognizes α-MSH and desacetyl-α-MSH, but not ACTH1-24, ACTH1-39, γ-MSH or β-712	
MSH, was made in-house. O-(6-Chlorobenzotriazol-1-yl)-N,N,N′,N′-713	
tetramethyluronium hexafluorophosphate (HCTU), and Fmoc-amino acids were 714	
purchased from GL Biochem (Shanghai, China). Fmoc-amino acids were supplied 715	
with the following side-chain protection: Fmoc-Asn(Trt)-OH, Fmoc-Arg(Pbf)-OH, 716	
Fmoc-Glu(OtBu)-OH, Fmoc-Gln(Trt)-OH, Fmoc-His(Trt)-OH, Fmoc-Lys(Boc)-OH, 717	
Fmoc-Ser(tBu)-OH, Fmoc-Trp(Boc)-OH, Fmoc-Tyr(tBu)-OH. Fmoc-Phe-718	
OCH2PhOCH2CH2CO2H (Fmoc-Phe-HMPP) was purchased from PolyPeptide Group 719	
(Strasbourg, France). N,N-Diisopropylethylamine (iPr2NEt), piperidine, acetic 720	
anhydride (Ac2O), N,N′-diisopropylcarbodiimide (DIC), 3,6-dioxa-1,8-octane-721	
dithiol (DODT), formic acid, 1-methyl-2-pyrrolidinone (NMP) and 722	
triisopropylsilane (iPr3SiH) were purchased from Sigma-Aldrich (St. Louis, 723	
Missouri). N,N-Dimethylformamide (DMF) and acetonitrile (MeCN) were supplied 724	
from Scharlau (Barcelona, Spain). Dichloromethane (CH2Cl2) was purchased from 725	
ECP Limited (Auckland, New Zealand). Trifluoroacetic acid (TFA) was purchased 726	
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from Halocarbon (River Edge, New Jersey). Aminomethyl polystyrene resin was 727	
synthesized following literature procedures [1, 2].   728	
 729	
2.  Synthesis, purification and analysis of “KKRR” native ACTH1-39, “QKQR” 730	
mutant ACTH1-39 and acetyl-“QKQR” mutant ACTH1-39.  731	
Aminomethyl polystyrene resin (0.1 mmol) was swollen in CH2Cl2 (5 mL, 30 min), 732	
drained and then reacted with Fmoc-Phe-HMPP (2.0 equiv), and DIC (2.0 equiv) in 733	
CH2Cl2 (2.0 mL) for 2 h at room temperature. Subsequent steps of Fmoc SPPS were 734	
performed using the Fmoc/tBu strategy and Liberty 12 Microwave Peptide 735	
Synthesizer (CEM Corporation, Mathews, NC). All amino acid couplings were 736	
performed as single coupling cycles, with the exception of Fmoc-Arg(Pbf)-OH and 737	
Fmoc-His(Trt)-OH where a double coupling cycle was performed as part of a 738	
synthetic protocol recommended by CEM Microwave Technology. Protected amino 739	
acids were incorporated using Fmoc-AA-OH (5.0 equiv, 0.2 M), HCTU (4.5 equiv, 740	
0.45 M), and iPr2NEt (10 equiv, 2 M) in DMF, for 5 min, at 25 W and maximum 741	
temperature of 75 ºC, except Fmoc-Arg(Pbf)-OH and Fmoc-His(Trt)-OH. Fmoc-742	
Arg(Pbf)-OH was initially coupled for 25 min at room temperature which was 743	
followed by the second coupling for 5 min, at 25 W and maximum temperature of 72 744	
ºC. Fmoc-His(Trt)-OH was initially coupled for 10 min at room temperature which 745	
was followed by the second coupling for 5 min, at 25 W and maximum temperature 746	
of 50 ºC The Fmoc group was removed using 20% piperidine in DMF (30 s followed 747	
by a second deprotection for 3 min at 62 W and maximum temperature of 75 ºC). For 748	
the synthesis of the acetyl-“QKQR” Mutant ACTH1-39 the final N-acetylation of the 749	
free Nα-amino group of N-terminal serine was performed using 20% Ac2O in NMP (2 750	
x). Resin cleavage and removal of the amino acid side-chain protecting groups was 751	
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undertaken by incubating the resin in TFA/iPr3SiH/H2O/DODT (v/v/v/v; 94/1/2.5/2.5) 752	
cleavage cocktail for 2 h at room temperature. The crude peptides were precipitated 753	
and triturated with cold diethyl ether, isolated (centrifugation), dissolved in 50% 754	
MeCN (aq) containing 0.1% TFA and lyophilized. 755	
Analytical reverse phase high-performance liquid chromatography (RP-HPLC) was 756	
performed using a Dionex P680 using Waters XTerraÒ analytical column (MS C18, 757	
150 mm x 4.6 mm; 5 µm), at a flow rate of 1 mL/min, and using the 5%B to 65%B 758	
over 20 min, ca. 3%B per min gradient system. The solvent system used was A (0.1% 759	
TFA in H2O) and B (0.1% TFA in MeCN) with detection at 210 nm, 254 nm, and 280 760	
nm. The ratio of products was determined by integration of spectra recorded at 210 761	
nm. 762	
A Hewlett Packard (Palo Alto, CA) 1100MSD mass spectrometer was used for ESI-763	
MS analysis in the positive mode. Peptides were purified using a Waters 600E system 764	
using Waters XTerraÒ semi-preparative column (C18, 300 mm x 19 mm; 10 µm), at a 765	
flow rate of 10 mL/min, and using the 5%B to 20%B over 15 min, ca. 1%B per min, 766	
and then 20%B to 75%B over 550 min, ca. 0.1%B per min gradient system. Fractions 767	
were collected, analyzed by either RP-HPLC or ESI-MS, pooled and lyophilized, to 768	
give the “KKRR” Native ACTH1-39 (11.8 mg, 98% purity); Rt 13.30 min; m/z (ESI-769	
MS) 917.1 ([M + 5H]5+ requires 917.4), “QKQR” Mutant ACTH1-39 (6.0 mg, 99% 770	
purity); Rt 13.41 min; m/z (ESI-MS) 911.5 ([M + 5H]5+ requires 911.8), and acetyl-771	
“QKQR” Mutant ACTH1-39 (19.2 mg, 98% purity); Rt 13.70 min; m/z (ESI-MS) 920.0 772	
([M + 5H]5+ requires 920.8), as white amorphous solids. 773	
 774	
3.  Testing mutations in ACTH1-39 for effects on ACTH1-39 functional activity. 775	
3.1. In Vivo: Dexamethasone-suppression test.  776	
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Adult male Pomcwt/wt mice were acclimatized to handing for 1 week before the start of 777	
the experiment. At 0900 hour on the day of experiment each mouse received 0.4 mg 778	
(100 µL) dexamethasone sodium phosphate by intraperitoneal (ip) injection. After 2 779	
h, the mice received via subcutaneous injection 100 µL vehicle (0.5% bovine serum 780	
albumin [BSA] in phosphate buffered saline [PBS]), ACTH1-39 (1 µg) or mutant 781	
ACTH1-39 peptide (1 µg). One hour later, the mice were euthanized by cervical 782	
dislocation, blood collected by cardiac puncture and plasma prepared for steroid 783	
hormone measurement.  784	
3.2. In Vitro: Cre-luciferase activity.  785	
HEK293 cells were transfected with human MC4R, cAMP responsive luciferase 786	
construct (LUC) and internal control plasmid, pRL-CMV (Promega Corp., Madison, 787	
Wisconsin, USA) which constitutively expresses Renilla luciferase. After 788	
transfection, cells were serum starved for 8 h before increasing doses of peptide were 789	
added and the cells incubated for 16 h at 37°C. The cells were then lysed and 790	
luciferase reporter activity analyzed as previously described [3]. 791	
 792	
4.   MALDI-TOF MS to identify POMC-derived peptides expressed in pituitary 793	
cryosections and pituitary lysates. 794	
Sections (10 µM) of snap-frozen Pomcwt/wt and Pomctm1/tm1 adult mouse pituitaries 795	
were sectioned at -21°C on a cryostat and mounted onto either a glass slide for H&E 796	
staining or a MALDI-TOF plate ready for Mass Spectrometry (MS). The adjacent 797	
sections on the glass slide were used to determine which sections on the MALDI-TOF 798	
plate included the pars intermedia of the pituitary. Spots (1 µL) of 10 µM purified 799	
peptide stocks (diacetyl-α-MSH, α-MSH, desacetyl-α-MSH and ACTH1-24) were also 800	
spiked on the MALDI-TOF plate to get near-point calibration data for molecular 801	
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weight determination. The MALDI-TOF plates with sections and peptides were dried 802	
for ≥30 min in a vacuum dessicator. Matrix (αCyano-4-hydroxycinnamic acid in 50% 803	
acetonitrile in sterile water with 0.1% trifluoroacetic acid [TFA]) was applied 804	
manually over tissues and peptides and allowed to thoroughly dry before the plate was 805	
read in a Voyager DE-Pro Mass Spectrometer (Applied Biosystems, Carlsbad, CA).  806	
For tissue lysates, each pituitary was lysed in 100 µL lysis buffer (1 cOmplete™, 807	
Mini Protease Inhibitor Cocktail tablet (Roche Life Science, Auckland, New Zealand) 808	
dissolved in 10 mL sterile water, 0.1% TFA) on ice using a plastic rod to disrupt 809	
tissue followed by sonication in a water bath at 4°C for 2 min. The lysate was then 810	
centrifuged at 13,000 rpm at 4C for 2 min. An aliquot (1 µL) of supernatant was 811	
mixed with 1 µL of matrix, spotted onto a MALDI-TOF plate, thoroughly dried and 812	
then read in a Voyager DE-Pro Mass Spectrometer.  813	
 814	
5.   Immunoprecipitation and MS to identify the peptide recognized by KM4 815	
antibody in Pomctm1/tm1 mouse pituitary. 816	
KM4 antibody cross-linked to Protein A Sepharose 4 Fast Flow Affinity beads 817	
(Roche Diagnostics) was used to pull-down peptides in pituitary lysates. The bound 818	
peptides were identified using MALDI-TOF and LC-ESI Mass spectrometry after 819	
elution from the beads. The beads were prepared for cross-linking by centrifuging 400 820	
µL Protein A Sepharose 4 bead slurry in an eppendorf tube at 6000rpm for 2 min and 821	
removing the ethanol supernatant. The beads were then washed 3 x with 1 mL binding 822	
buffer (0.1% BSA in PBS, pH 7.4) by gentle rotation of tubes at room temperature 823	
(RT) for 10 min followed by centrifugation and aspiration of supernatant. KM4 824	
antibody (400 µL serum) was bound to the sepharose beads in the presence of 400 µL 825	
binding buffer by mixing with rotation overnight at 4°C in the presence of 826	
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cOmplete™, Mini Protease Inhibitor Cocktail. The beads were then pelleted by 827	
centrifugation, the supernatant discarded and the beads were washed once with 400 828	
µL binding buffer followed by 3 washes of 400 µL PBS. The bifunctional coupling 829	
reagent, dimethyl pimelindiimidate (DMP) (Sigma-Aldrich New Zealand Ltd, 830	
Auckland, NZ) (400 µL), pH 8-9, was added to the beads and they were mixed by 831	
rotation for 30 min at RT. Following centrifugation and aspiration of DMP, the beads 832	
were washed with 400 µL wash buffer (0.2 M Triethanolamine [Sigma-Aldrich New 833	
Zealand Ltd] in PBS) by gentle mixing with rotation for 5 min at RT. The addition of 834	
fresh DMP followed by these wash steps was repeated two more times. Quenching 835	
buffer (50 mM ethanolamine hydrochloride [Sigma-Aldrich New Zealand Ltd] in 836	
PBS, 400 µL) was added to beads followed by gentle mixing by rotation for 5 in at 837	
RT, centrifugation and aspiration of supernatant. To remove excess unlabeled 838	
antibody, the beads were washed with 0.1 M glycine, pH 3.0. The beads were washed 839	
1x with PBS for 5 min at RT, 3x with PBS + 0.01% sodium azide, 0.1% BSA and 840	
then stored in the final wash at 4°C.  841	
Immunoprecipitation using the KM4 cross-linked beads was validated using pure 842	
synthetic α-MSH and desacetyl-α-MSH peptides. Sepharose-KM4 cross-linked beads 843	
(20 µL slurry) were transferred from the stock into two eppendorf tubes, centrifuged 844	
and washed 3x with PBS as previously described. Purified α-MSH (10 µM, 10 µL) or 845	
desacetyl-α-MSH (10 µM, 10 µL) was bound to Sepharose-KM4 beads in the 846	
presence of 200 µL PBS for 45 min at RT with gentle mixing. Following 847	
centrifugation and aspiration of supernatant, the beads were washed 10x with 200 µL 848	
wash buffer (50 mM ammonium bicarbonate, pH 8.2) and the final wash was pipetted 849	
into a P10 filter tip which when run dry, left the Sepharose-KM4 bead complexed 850	
with peptide in the filter. The filter was then washed 10x with 200 µL sterile water 851	
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before the peptides were eluted into a low-bind eppendorf tube with 10 µL elution 852	
buffer (0.1% TFA in acetonitrile). 1 µL of each eluted peptide was spotted onto a 853	
MALDI-TOF plate and left to dry in a fume hood overnight. Spots (10 µL) of 2.5 fold 854	
dilutions of the 10uM purified peptide stock were included on the plate as positive 855	
controls. The following day the spots were analyzed on a Voyager Pro MALDI-TOF 856	
Mass Spectrometer as previously described. 857	
Each snap-frozen Pomctm1/tm1 mouse pituitary was lysed in 300 µL lysis buffer (50 858	
mM Tris-HCL, 150 mM NaCL, pH 8.0) containing 0.1% Brij 35 (Sigma-Aldrich New 859	
Zealand Ltd) + 1 cOmplete™ Mini Protease Inhibitor Cocktail tablet per 10 mL at 860	
4°C using a small plastic homogenizing rod followed by 2 min water bath sonication 861	
at 4°C. The homogenate was centrifuged at 13,000 rpm for 2 min at 4°C and the 862	
supernatant collected. The supernatant was then incubated with 10 µL Sepharose-863	
KM4 beads at RT for 45 min with gentle mixing. Following centrifugation and 864	
aspiration of supernatant the beads were washed as described above for peptide 865	
binding and then eluted with 20 µL matrix ready for spotting on MALDI-TOF plate 866	
as previously described. 867	
To identify the peptide in Pomctm1/tm1 pituitary that immunoprecipitates with KM4, 868	
three Pomctm1/tm1 pituitaries were immunoprecipitated using KM4 antibody and 1 µL 869	
of each eluate was analyzed by MALDI-TOF to confirm the presence of a peak at m/z 870	
4598. The peptide eluates were pooled, diluted 10x in 0.1% formic acid in water and 871	
then loaded onto an Oasis Mixed mode Cation Exchange (MCX) SPE cartridge 872	
(Waters, Milford, MA, USA). The loaded MCX cartridge was washed 1x with 1 mL 873	
0.1N HCL followed by 1x with 1 mL methanol and then the peptides were eluted with 874	
1 mL 5% ammonium hydroxide in methanol. The eluant was concentrated to ~10-20 875	
µL using centrifugation under vacuum, and then digested with 25 ng/mL sequencing-876	
	 37	
grade trypsin (Promega, Madison, WI, USA). The resulting digest was separated on a 877	
0.3 x 100 mm Zorbax 300SB-C18 column (Agilent, Santa Clara, CA, USA). The 878	
HPLC gradient between Buffer A (0.1% formic acid in water) and Buffer B (0.1% 879	
formic acid in acetonitrile) was formed at 6 µL/min as follows: 10% B for the first 3 880	
min, increasing to 35% B by 33 min, increasing to 95% B by 36 min, held at 95% 881	
until 39 min, back to 10% B at 40.5 min and held there until 48 min. The LC effluent 882	
was directed into the Ionspray source of QSTAR XL hybrid Quadrupole-Time-of-883	
Flight MS (Applied Biosystems, Foster City, CA, USA) scanning from 300-1600 m/z. 884	
the top three most abundant multiply-charged peptides were selected for MS/MS 885	
analysis (100-1600 m/z). The MS and HPLC system were under the control of the 886	
Analyst QS 2.0 software package (Applied Biosystems). The resulting MS/MS 887	
spectra were searched against the Mouse subset of NCBI’s protein database (146781 888	
sequences, June 2012) using Mascot software (Matrix Science, London, UK). 889	
 890	
6.   Testing acetyl-QKQR mutant ACTH1-39 peptides for coupling of MC2R and 891	
MC4R to adenylyl cyclase in vitro. 892	
HEK293 cells stably expressing mouse MC4R (mMC4R) developed previously [4, 5] 893	
were used to compare acetyl-QKQR mutant ACTH1-39 with ACTH1-24, ACTH1-39 and 894	
QKQR mutant ACTH1-39 to determine whether acetylation of QKQR mutant ACTH1-895	
39 alters QKQR mutant ACTH1-39 activation of the MC4R. 896	
HEK293 cells stably expressing mMRAP developed previously [6] and transiently 897	
transfected with mMC2R were used to compare acetyl-QKQR ACTH1-39 with 898	
ACTH1-24, ACTH1-39 and QKQR mutant ACTH1-39 to determine whether acetylation 899	
of QKQR mutant ACTH1-39 alters mutant QKQR ACTH1-39 activation of the MC2R. 900	
The mMC2R was obtained by PCR from C57BL/6J mouse retroperitoneal fat cDNA 901	
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and subcloned into pcDNA3.1 vector (InVitrogen New Zealand Ltd., Auckland, NZ). 902	
PCR for mMC2R was performed on 2 µL cDNA using iProof High Fidelity DNA 903	
polymerase (BioRad Laboratories Pty, Auckland, NZ) using forward (5’-904	
atcggatccGTAAGTCAACGGCAAACACCACC-3’) and reverse (5’-905	
gactcgagCTAATACCGGTTGCAGAAGAGCA-3’) and the following conditions: 906	
denature at 98°C for 1 min followed by 34 cycles of denature at 98°C, anneal at 907	
62.5°C for 5 s and elongate at 72°C for 10 s, and a final 7 min extension at 72°C. The 908	
primers encoded restriction enzyme sites for BamH1 and Xho1 for directional 909	
cloning. The recombinant DNA was verified by sequencing and the mMC2R coding 910	
sequence aligned with GenBank accession number XM 006525713.1. Adenylyl 911	
cyclase activity was determined directly by measuring the ability of cells to convert 912	
[3H]adenine to [3H]cAMP following exposure of the cells to increasing doses of 913	
peptide as described previously [5]. 914	
 915	
7.  MALDI-TOF Imaging MS. 916	
Pomcwt/wt and Pomctm1/tm1 pituitaries from adult mice were dissected, snap frozen and 917	
stored at -80°C. Pituitary glands were mounted on a cryostat specimen holder with a 918	
small amount of Tissue-Tek OCT Compound (Siemens NZ Ltd.) at the base of the 919	
tissue only. Transverse sections (12 µm) were cut and collected alternately via thaw-920	
mounting on glass slides (for histological staining) or stainless steel MALDI plate (for 921	
MALDI image analysis). For histological analysis, sections on glass slides were H&E 922	
stained using standard procedures. Sections for MALDI imaging analysis were placed 923	
in a vacuum desiccator for 30 min prior to undergoing matrix application. A thin even 924	
coating of 2,5-dihydroxybenzoic acid (DHB) matrix was applied to pituitary sections 925	
using vacuum sublimation. Briefly, the MALDI plate was placed in an in-house 926	
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fabricated glass sublimation apparatus and a vacuum of 4.0 x 10-2 Torr established. 927	
Heat (~ 120°C) was applied to the chamber via a sand bath for 6 min to achieve an 928	
optimal DHB matrix coating. Following matrix application, matrix was recrystalized 929	
using a simple humidity chamber. The MALDI plate was attached to the lid of a glass 930	
petri dish and the chamber was closed and humidified with a piece of filter paper 931	
saturated with 1 mL of 83.7% acetonitrile and 5% trifluoroacetic acid for 4 min at 932	
room temperature. The chamber was then opened and the pituitary sample dried at 933	
room temperature. 934	
MALDI imaging was performed using a Voyager DE-Pro MALDI-TOF MS 935	
operating in linear positive mode with an accelerating potential of +25 kV. An 936	
external calibration was applied to the instrument prior to analysis. MALDI imaging 937	
data sets were collected over whole mouse pituitary gland sections (MMSIT, 938	
Novartis, Basel Switzerland) with a raster step size of 60 µm and 25 laser shots per 939	
spectrum. Each data set consisted of ~1000 individual sampling locations, each 940	
representing one pixel in the resultant image. Data were normalized to total ion 941	
current and molecular images reconstituted using BioMap software (Novartis, Basel, 942	
Switzerland). Each m/z signal was plotted ± 0.05% of the molecular mass. For display 943	
purposes, the data were interpolated and pixel intensities were normalized to the 944	
maximum intensity for each m/z displayed in the software to use the entire dynamic 945	
range. Assignments of peptide identifications were made using tandem MS (data not 946	
shown). 947	
  948	
8.   Plasma corticosterone assay. 949	
Blood was collected from cardiac puncture on isoflurane-anesthetized mice or mice 950	
euthanized by cervical dislocation for the dexamethasone suppression tests. Plasma 951	
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corticosterone was either measured using a commercial kit (Immunodiagnostics, Tyne 952	
and Wear, UK) according to the manufacturer’s instructions or using triple 953	
quadrupole MS. For triple quadrupole MS, 100 µL of internal standard solution (6 ng 954	
mL-1 corticosterone-d8 in water) was added to 85 µL plasma. Steroids were extracted 955	
using 1 mL of ethyl acetate (Merck, KGaA Darnstadt, Germany). After removal of 956	
the organic supernatant, samples were dried by vacuum concentration (Savant 957	
SC250EXP, Thermo Scientific, Asheville, NC, USA), resuspended in 60 µL of 958	
mobile phase (65% methanol (Merck) and 35% water), and transferred to HPLC 959	
injector vials. 12 µL was injected onto an HPLC MS system consisting of an Accela 960	
MS pump and autosampler followed by an Ion Max APCI source on a Finnigan TSQ 961	
Quantum Ultra AM triple quadrapole MS, all controlled by Finnigan Xcalibur 962	
software (Thermo Electron Corporation, San Jose, CA, USA). The mobile phase was 963	
a gradient of methanol and water, flowing at 300 µL.min-1 through a Luna HST 964	
2.6µm C18(2) 100 x 3.0mm column at 40ºC (Phenomenex, Auckland, New Zealand). 965	
Retention times were 4.3min for both corticosterone and corticosterone-d8. Ionisation 966	
was in positive mode for corticosterone and Q2 had 1.2 mTorr of argon. The mass 967	
transitions followed were corticosterone 347.15 → 121.1 at 27 V and corticosterone-968	
d8 355.2 → 125.2 at 24 V.  All samples were analysed in one assay.  969	
 970	
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SUPPLEMENTARY FIGURES 995	
Supplementary Figure 1. 996	
Validation that QKQR mutant ACTH functions similar to native ACTH1-39. (A) 997	
ACTH-stimulated plasma corticosterone in dexamethasone-suppressed adult male 998	
mice. Two-hours post dexamethasone treatment mice (n=4 /group) were treated with 999	
vehicle (Sham), native ACTH1-39 (KKRR) or mutant (QKQR, KGGR, KQRQ) 1000	
	 42	
ACTH1-39 peptide. Data is shown as mean ± SEM ****, p < 0.0001. (B) Native 1001	
ACTH1-39, mutant (QKQR) ACTH1-39 and α-MSH stimulated human MC4R co-1002	
transfected with Cre-luciferase reporter into HEK293 cells. Data is shown as mean ± 1003	
SEM for 2-3 independent experiments. (C) Plasma corticosterone levels for male 1004	
(168-216 days) and female (170-208 days) mice. Data are shown as mean ± SEM. 1005	
	1006	
Supplementary Figure 2. 1007	
MALDI-TOF MS detects diacetyl-α-MSH and α-MSH in Pomcwt/wt but not in 1008	
Pomctm1/tm1 whole pituitary lysates. Mass spectra are shown for representative 1009	
Pomcwt/wt (A) and Pomctm1/tm1 (B) whole pituitary lysates. α-MSH (m/z 1664), 1010	
diacetyl-α-MSH (m/z 1707) and Arg-CLIP (1-21) (m/z 2359) are detected in 1011	
Pomcwt/wt but not in Pomctm1/tm1 pituitary lysates. Vasopressin (m/z 1085), J peptide 1012	
(m/z 1941) and a peptide that may be β-lipotropin (m/z 4438; 9Da larger than β-1013	
lipotropin), are detected in both Pomcwt/wt and Pomctm1/tm1 pituitary lysates. Relatively 1014	
weak signal is observed at m/z 4638 for Pomctm1/tm1 but not Pomcwt/wt pituitary 1015	
lysates. 1016	 	1017	
Supplementary Figure 3. 1018	
N-terminal acetylation does not alter QKQR mutant ACTH1-39 at the mMC4R 1019	
but it abolishes its activity at the mMC2R. (A) Acetyl-QKQR ACTH1-39 and 1020	
QKQR ACTH1-39 function identically coupling the mMC4R transfected into HEK293 1021	
cells to adenylyl cyclase. Both QKQR mutant ACTH1-39 (EC50 = 4.95 ± 0.05 x 10-9M) 1022	
and acetyl-QKQR mutant ACTH1-39 (EC50 = 4.74 ± 0.05 x 10-9M) are two-fold less 1023	
potent compared with native ACTH1-39 (EC50 = 2.23 ± 0.06 x 10-9M). (B) QKQR 1024	
	 43	
ACTH1-39 is a full agonist coupling the mMC2R transfected into HEK293 cells to 1025	
adenylyl cyclase but it is 82 fold less potent compared with ACTH1-39. In contrast, 1026	
Acetyl-QKQR ACTH 1-39 is inactive coupling the mMC2R to adenylyl cyclase. Data 1027	
is shown as mean ± SEM for three independent experiments.  1028	
 1029	
Supplementary Figure 4. 1030	
α-MSH and desacetyl-α-MSH are stable dissolved in PBS when stored at 37 °C 1031	
for 14 days. MALDI-TOF MS detects (A, C, E) intact α-MSH and (B, D, F) intact 1032	
desacetyl-α-MSH following (A, B) 7, (C, D) 10 and (E, F) 14 days storage in PBS and 1033	
incubation at 37 °C. There is no detectable degradation or oxidation of either peptide 1034	
after 14 days storage. The small peaks observed on MS are likely due to the PBS used 1035	
to dissolve the peptides. 1036	
 1037	
 1038	
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